Article information
Full text is only aviable in PDF
Bibliografía
[1.]
J. Koch-Weser.
Fatal reactions to drug therapy.
N Engl J Med, 291 (1974), pp. 302-303
[2.]
J.A.D. Cooper Jr., D.A. White, R.A. Mattay.
Drug-induced pulmonary disease.
Part I. Cytotoxic drugs. Am Rev Respir Dis, 133 (1986), pp. 321-340
[3.]
J.A.D. Cooper Jr., D.A. White, R.A. Mattay.
Drug-induced pulmonary disease. Part II. Non-cytotoxic drugs.
Am Rev Respir Dis, 133 (1986), pp. 488-505
[4.]
K.L. Lantot, C.A. Naranjo.
Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drugs events.
Clin Pharmacol Ther, 58 (1995), pp. 692-698
[6.]
J.T. Santamauro, D.E. Stover, K. Jules Elysee, J.R. Maurer.
Lung transplantation for chemotherapy-induced pulmonary fibrosis.
Chest, 105 (1994), pp. 310-312
[7.]
R.V. Lourenco, C.S. Garrand.
Neumopatía intersticial difusa.
Medicina Interna, 2.ª, pp. 682-689
[8.]
G.W. Cannon.
Methotrexate pulmonary toxicity.
Reum Dis Clin North Am, 23 (1997), pp. 917-937
[9.]
E.C. Rosenow III..
Drug-induced lung diseases.
Textbook of internal medicine., pp. 1.939-1.943
[10.]
S.A. Edlavitch.
Adverse drug event reporting. Improving the low U.S. reporting rates.
Arch Intern Med, 148 (1988), pp. 1.499-1.503
[11.]
T.E. Albertson, W.F. Walby, R.W. Derlet.
Stimulant-induced pulmonary toxicity.
Chest, 108 (1995), pp. 1.140-1.149
[12.]
H. Kreisman, N. Wolkove.
Pulmonary toxicity of antineoplastic therapy.
Semin Oncol, 19 (1992), pp. 508-520
[13.]
D.E. Stover, M.B. Zaman, S.I. Hadju, M. Lange, J. Gold, D. Armstrong.
Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host.
Ann Intern Med, 101 (1984), pp. 1-7
[14.]
F. Cervantes, C. Salgado, E. Montserrat, C. Rozman.
Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis.
Lancet, 336 (1990), pp. 1.130
[15.]
A.S. Rogers, E. Israel, C.R. Smith, D. Levine, A.M. McBean, C. Valiente, et al.
Physician knowledge, attitudes, and behavior related to reporting adverse drug events.
Arch Intern Med, 148 (1988), pp. 1.596-1.600
[16.]
J.F. Murray.
The normal lung.
2.ª, WB Saunders Co, (1986), pp. 183-210
[17.]
L. Feinberg, W.D. Travis, V. Ferrans, N. Sato, H.F. Bernton.
Pulmonary fibrosis associated with tocainide: report of a case with literature review.
Am Rev Respir Dis, 141 (1990), pp. 505-508
[18.]
J.J. DeGeorge, C.H. Ahn, P.A. Andrews, M.E. Brower, Y.S. Choi, M.Y. Chun, et al.
Considerations for toxicology studies of respiratory drug products.
Regul Toxicol Pharmaeol, 25 (1997), pp. 189-193
[19.]
T. Ishizaki, F. Sasaki, S. Ameshima, K. Shiozaki, H. Takahashi, Y. Abe, et al.
Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis.
Eur Respir J, 9 (1996), pp. 2.691-2.696
[20.]
A. Bitton, M.A. Peppereom, J.P. Manrahan, M.P. Upton.
Mesalamine-induced lung toxicity.
Am J Gastroenterol, 91 (1996), pp. 1.039-1.040
[21.]
L. Abenhaim, Y. Moride, F. Brenot, S. Rich, J. Benichou, X. Kurz, et al.
Appetite-suppresant drugs and the risk of primary pulmonary hypertension.
N Engl J Med, 335 (1996), pp. 609-616
[22.]
A. Marruchella, G. Fiorenzano, A. Marizzi, G. Rossi, P.L. Chiodera.
Diffuse alveolar damage in a patient treated with gemeitabidine.
Eur Respir J, 11 (1998), pp. 504-506
[23.]
S.I. Bearman, B.A. Overmoyer, B.J. Bolwell, C.W. Taylor, E.J. Shpall, R.J. Cagnoni, et al.
High-dose chemotherapy with autologus peripheral blood progenitor cell support for primary brest cáncer in patients with 4-9 involved axillary lymph nodes.
Bone Marrow transplant, 20 (1997), pp. 931-937
[24.]
R.D. Reynolds, R.M. Smith.
Nebulized bacteriostatic saline as a cause of bronchitis.
J Fam Pract, 40 (1995), pp. 535-536
[25.]
M.R. Maya, F. Carrión, J. Díaz.
Broncoespasmo paradójico en la exploración funcional respiratoria.
Arch Bronconeumol, 35 (1999), pp. 51
[26.]
S.W. Malik, J.L. Myers, R.A. DeRemee, U. Specks.
Lung toxicity associated with cyclophosphamide use.
Two distinct patterns. Am J Respir Crit Care Med, 154 (1996), pp. 1.851-1.856
[27.]
A.J.J. Wood, J.A. Oates.
Reacciones adversas a los fármacos.
12.ª, pp. 443-450
[28.]
R. Vida Pía.
Enfermedades pulmonares ocupacionales producidas por fármacos y substancias químicas.
Neumología básica., pp. 178-184
[29.]
B.K. Park, M. Pirmohamed, N.R. Kitteringham.
The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity.
Pharmacol Ther, 68 (1995), pp. 385-424
[30.]
J.C. Reed.
Chest radiology.
4.ª, Mosby, (1997), pp. 227-248
[31.]
J.C. Reed.
Chest radiology.
4.ª, Mosby, (1997), pp. 295-313
[32.]
J.M. Aronchick, W.B. Gefter.
Drug-induced pulmonary disease: an update.
J Thorac Imaging, 6 (1991), pp. 19-29
[33.]
R.L. Morteson, R.M. Bogin, T.E. King Jr..
Interstitial lung disease.
Recent advances in respiratory medicine., pp. 163-184
[34.]
J.L. Rau Jr..
Respiratory care pharmacology.
4.ª, Mosby, (1994), pp. 1-31
[35.]
C.R. Taylor.
Diagnostic imaging techniques in the evaluation of drug-induced pulmonary disease.
Clin Chest Med, 11 (1990), pp. 87-94
[36.]
E.F. Patz Jr., W.P. Peters, P.C. Goodman.
Pulmonary drug toxicity following high-dose chemotherapy with autologous bone marrow transplantation: CT findings in 20 cases.
J Thorac Imaging, 9 (1994), pp. 129-134
[37.]
E.A. Bellamy, J.E. Flusband, R.M. Blaquiere, M.R. Law.
Bleomycinrelated lung damage: CT evidence.
Radiology, 156 (1985), pp. 155-158
[38.]
E.A. Bellamy, D. Nicholas, J.E. Husband.
Quantitative assessment of lung damage due to bleomycin using computed tomography.
Br J Radiol, 60 (1987), pp. 1.205-1.209
[39.]
J. Kuhlman, C. Teigen, H. Ren, H.R. Hruban, G.M. Hutchins, K. Fishman, et al.
Amiodarone pulmonary toxicity: CT findings in symptomatic patients.
Radiology, 177 (1990), pp. 121-125
[40.]
M.G. Stein, T. Demarco, G. Gamsu, W. Finkbeiner, J.A. Golden.
Computed tomography: pathologic correlation in lung disease due to tocainide.
Am Rev Respir Dis, 137 (1988), pp. 458-460
[41.]
M.J. Rimmer, A.K. Dixon, C.D. Flower, K. Sikora.
Bleomycin lung: computed tomographic observations.
Br J Radiol, 58 (1985), pp. 1.041-1.045
[42.]
C. Bekerman, P.B. Hoffer, J.D. Bitran, R.G. Gupta.
Galium-67 citrate imaging studies of the lung.
Semin Nucl Med, 10 (1980), pp. 286-301
[43.]
D.L. Coleman, R.S. Hattner, J.M. Luce, P.M. Dodek, J.A. Golden, J.F. Murray.
Correlation between gallium lung scans and fiberoptic bronchoscopy in patiens with suspected Pneumocystis carinii pneumonia and the adquired immune deficiency syndrome.
Am Rev Respir Dis, 130 (1984), pp. 1.166-1.169
[44.]
E.L. Kramer, J.J. Sanger, S.M. Garay, J.B. Greene, S. Tiu, H. Banner, et al.
Gallium-67 scans of the chest in patients with acquired immunodeficiency syndrome.
J Nucí Med, 28 (1987), pp. 1.107-1.114
[45.]
H.D. Specht, P.H. Brown, J.E. Haines, M. McNeill.
Gallium-67 lung index computerization in intersticial pneumonitis.
J Nucl Med, 28 (1987), pp. 1.826-1.830
[46.]
M.D. Dake, R. Hattner, M.L. Warnock, J.A. Golden.
Gallium-67 lung uptake associated with amiodarone pulmonary toxicity.
Am Heart J, 109 (1985), pp. 1.114-1.116
[47.]
C.R. Taylor, H.D. Sostman, J.C. Gore, G.W. Smith.
Proton relaxation times in bleomycin-induced lung injury.
Invest Radiol, 22 (1987), pp. 621-626
[48.]
S. Vinitski, M.G. Pearson, S.T. Karlik, W.K. Morgan, L.S. Carey, G. Perkins, et al.
Differentiation of parenchymal lung disorders with in vitro proton nuclear magnetic resonance.
Magn Reson Med, 3 (1986), pp. 120-125
[49.]
G.J.W. Smith.
The histopathology of pulmonary reactions to drugs.
Clin Chest Med, 11 (1990), pp. 95-117
[50.]
A.W. Jones.
Bleomycin lung damage: the pathology and nature of the lesion.
Br J Dis Chest, 72 (1978), pp. 321-326
[51.]
F. Morell.
Eosinofilia pulmonar.
Neumología básica, pp. 200-205
[52.]
L.C. Watters.
Chronic alveolar filling disease.
Interstitial lung disease, 2.ª, pp. 327-328
[53.]
H.D. Tazelaar, J.L. Myers, C.W. Drage, T.E. King, S. Aguayo, T.V. Colby.
Pulmonary disease associated with L-trytophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features.
Chest, 97 (1990), pp. 1.032-1.036
[54.]
J.J. Hoefnagel, R.L. van Leeuwen, H. Mattie, M.Y. Bastiaens.
Bijwerkingen van minocycline in de behandeling van acné vulgaris.
Ned Tijdschr Geneeskd, 141 (1997), pp. 1.424-1.427
[55.]
P.C. Wong, W. Yew, C.F. Wong, H.Y. Choi.
Ethambutol-induced pulmonary infi Itrates with eosinophilia and skin involvement.
Eur Respir J, 8 (1995), pp. 866-868
[56.]
R. Fernández, J.A. Gullón, C. Riesgo, L. Molinos, J. Martínez.
Toxicidad pulmonar aguda por carbamazepina: a propósito de un caso.
Arch Bronconeumol, 30 (1994), pp. 471-472
[57.]
R.G. Andersson, K. Persson.
ACE inhibitors and their influence on inflamation, bronchial reativuty and cough.
Eur Heart J, 15 (1994), pp. 52-56
[58.]
A.S. Fauci, B.F. Haynes, P. Katz.
The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations.
Ann Intern Med, 89 (1978), pp. 660
[59.]
S. Romero, L. Hernández, J. Gil.
Bronquiolitis obliterante.
Actualizaciones SEPAR, pp. 27-49
[60.]
D.M. Geddes, B. Corrin, D.A. Brewerton, R.J. Davies, M. Turner-Warwick.
Progressive airway obliteration in adults and its association with rheumatoid arthritis.
Q J Med, 44 (1977), pp. 427-444
[61.]
A.U. Wells.
Du Bois RM.
Bronchiolitis in association with connective tissue disorders. Clin Chest Med, 14 (1993), pp. 655-666
[63.]
K.J. Schwartzman, D.M. Bowie, C. Yeadon, R. Fraser, D.E. Sutton, R.D. Levy.
Constrictive bronchiolitis obliterans associated with chrysotherapy.
Ann Rheum Dis, 42 (1983), pp. 593-596
[64.]
H.M. Hollingsworth.
Drug-related bronchiolitis obliterans organizing pneumonia.
Diseases of bronchioles., pp. 367-376
[65.]
J.M. Valle, D. Álvarez, J. Antúnez, L. Valdés.
Bronchiolitis obliterans organizing pneumonía secondary to amiodarone: a rare aetiology.
Eur Respir J, 8 (1995), pp. 470-471
[66.]
F. Ripollés, J. Redón, B. Martínez, J.M. Pascual, M.C. Gandía, J. García.
Toxicidad pulmonar por amiodarona.
Mejoría espontánea sin tratamiento corticoideo. An Med Intern (Madrid), 2 (1985), pp. 71-74
[67.]
P.J. Dean, K.D. Groshart, J.G. Porterfield, D.H. Iansmith, E.B. Golden Jr..
Amiodarone-associated pulmonary toxicity. A clinical and pathologic study of eleven cases.
Am J Clin Pathol, 87 (1987), pp. 713
[68.]
J. De Castro, Y. Viches, M. González.
Toxicidad pulmonar en el tratamiento del cáncer. Med Clin (Barc), 105 (1995), pp. 661-668
[69.]
J.M. Jimeno, E. Díaz-Rubio.
Tratamiento semanal con antraciclinas a bajas dosis: un análisis de las bases farmacológicas, actividad clínica y efectos secundarios.
Neoplasia, 4 (1987), pp. 165-174
[70.]
M. Arning, A.H. Heer-Sonderhoff, A. Wehmeier, W. Schneider.
Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia.
Eur J Clin Microbiol Infect Dis, 14 (1995), pp. 41-43
[71.]
J. Sanz, R. Ondiviela, J. Ortiz, F. Fernández.
Edema pulmonar no cardiogénico como complicación de un síndrome hemolíticourémico inducido por mitomicina C.
Neoplasia, 7 (1990), pp. 69-71
[72.]
B.A. Freeman, J.D. Crapo.
Biology of disease: free radicais and tissue injury.
Lab Invest, 47 (1982), pp. 412-426
[73.]
L.M. Antón, S. Harguindey, H. Verea.
Superóxido dismutasa como bloqueante de toxicidad pulmonar por bleomicina.
Neoplasia, 6 (1989), pp. 215-221
[74.]
S.H. Phan, J.C. Fantome.
Inhibition of bleomycin-induced pulmonary fibrosis.
Am Rev Respir Dis, 124 (1981), pp. 428-434
[75.]
M. Absher, J. Hildebran, L. Trombley, J. Woodcock-Mitchell, J. Marsh.
Characteristics of cultured lung fibroblasts from bleomycin-treated rats. Comparison with in vitro exposed normal fibroblasts.
Am Rev Respir Dis, 129 (1984), pp. 125-129
[76.]
G.L. Colice, M.A. Matthay, E. Bass, R.A. Matthay.
Neurogenic pulmonary edema.
Am Rev Respir Dis, 130 (1984), pp. 941-949
[77.]
H. Umezawa, K. Maeda, T. Takeuchi.
New antibiotics bleomycin A and B.
J Antibiotic, 19 (1966), pp. 200-209
[78.]
P. Zamora, J. Vicente.
González Barón M. Antibióticos antineoplásicos.
Oncología Clínica: fundamentos y patología general., pp. 248-258
[79.]
G. Lehne, K. Lote.
Pulmonary toxicity of cytotoxic and immuno suppressive agents.
Acta Oncológica, 28 (1990), pp. 113-124
[80.]
M.I. Waid-Jones, D.B. Coursin.
Perioperative considerations for patients treated with bleomycin.
Chest, 99 (1991), pp. 993-999
[81.]
M.T. Kuo, C.W. Haidle.
Characterization of chain breakage in DNA induced by bleomycin.
Biochem Biophys Acta, 335 (1974), pp. 109-114
[82.]
L. Nici, A. Santos-Moore, C. Kuhn, P. Caiabresi.
Modulation of bleomycin induced pulmonary toxicity in the hamster by antioxidant amifostine.
Cancer, 83 (1998), pp. 2.008-2.014
[83.]
S.A. Yousenr, J.D. Lifson, T.V. Colby.
Chemotherapy-induced eosinophilic pneumonía: Relation to bleomycin.
Chest, 88 (1985), pp. 103-106
[84.]
D.A. White, L.S. Schwartzberg, M.G. Kris, G.J. Bosl.
Acute chest pain syndrome during bleomycin infusions.
Cáncer, 59 (1987), pp. 1.582-1.585
[85.]
K. Jules-Elysee, D.A. White.
Bleomycin-induced pulmonary toxicity.
Clin Chest Med, 11 (1990), pp. 1-20
[86.]
A.B. Simpson, J. Paul, J. Graham, S.B. Kaye.
Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours.
Br J Cancer, 78 (1998), pp. 1.061-1.066
[87.]
J.S. Lazo, J.D. Catravas, C.N. Gillis.
Reduction in rabbit serum and pulmonary angiotensin-converting enzyme after subacute bleomycin treatment.
Biochem Pharmacol, 18 (1981), pp. 2.577-2.584
[88.]
R.H. Blum, S.K. Cárter, K. Agre.
A clinical review of bleomycin. A new antineoplastic agent.
Cancer, 31 (1973), pp. 903-914
[89.]
P.G. Gobbi, C. Pieresca, A. Frassoldati, M. Carotenuto, N. Di Renzo.
La Sala A et al. Vinblastine, bleomycin, and methotrexate chemothcrapy plus extendedfield radiotherapy in early, favorably presenting, clinically staged Hodkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience..
J Clin Oncol, 14 (1996), pp. 527-533
[90.]
K. Nygaard, N. Smith-Erichsen, R. Hatlevoll, et al.
Pulmonary complications after bleomycin, irradiation and surgery for esophageal cancer.
Cancer, 41 (1978), pp. 17-22
[91.]
E. Van der Wall, C.C. Schaake-Koning, N. Van Zandwijk, J.W. Baars, J.H. Schornagel, D.J. Richel, et al.
The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cáncer: a preliminary analysis.
Eur J Cancer, 32 (1996), pp. 1.490-1.497
[92.]
A.F. Tryka, W.A. Skornik, J.J. Godleski, J.D. Brain.
Potentiation of bleomycin-induced lung injury by exposure to 70% oxygen.
Morphologic assessment. Am Rev Respir Dis, 126 (1982), pp. 1.074-1.079
[93.]
N. Berend.
Protective effect of hypoxia on bleomycin lung toxicity in the rat.
Am Rev Respir Dis, 130 (1984), pp. 307-308
[94.]
K. Kawai, S. Hinotsu, M. Tomobe, H. Akaza.
Serum creatinine level during chemotherapy for testicular cancer as a possible preditor of bleomycin-induced pulmonary toxicity.
Jpn J Clin Oncol, 28 (1998), pp. 546-550
[95.]
N.W. Todd, W.P. Peters, A.H. Ost, V.L. Roggli, C.A. Piantadosi.
Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation.
Am Rev Respir Dis, 147 (1993), pp. 1.264-1.270
[96.]
R.V. Panganamala, N.R. Brownlee, H. Sprecher, D.G. Cornwell.
Evaluation of superoxide anion and singlet oxygen in the biosynthesis of prostaglandins froni eicosa-8,11,14-trienoic acid.
Prostaglandins, 7 (1974), pp. 21
[97.]
P.B. Luursema, M.A. Star-Kroesen, T.H.W. van der Mark, D.T. Sleyler, H.S. Koops, R. Peset.
Bleomycin-induced changes in the carbon monoxide transfer factor of the lungs and its components.
Am Rev Respir Dis, 128 (1983), pp. 880-883
[98.]
R.L. Comis.
Detecting bleomycin plumonary toxicity: a continued conundrum.
J Clin Oncol, 8 (1990), pp. 765-767
[99.]
J.W. Masón.
Drug-therapy: amiodarone.
N Engl J Med, 316 (1987), pp. 455-466
[100.]
D.G. Julian, A.J. Camm, G. Frangin, M.J. Janse, A. Muñoz, P.J. Schwartz, et al.
Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infartion.
Lancet, 349 (1997), pp. 667-674
[101.]
F. Manresa, A. Cequier, J. Escarrabill, M.J. Pérez-Ayuso, X. Sabater, C. Gausi.
Amiodarone and lung function.
Lancet, 2 (1983), pp. 1.367
[102.]
H.H. Rotmensch, M. Liron, M. Tupilski, S.H. Laniado.
Possible association of pneumonitis with amiodarone therapy.
Am Heart J, 100 (1980), pp. 412-413
[103.]
J. Roca, M. Heras, R. Rodríguez-Roisín, J. Magriñá, A. Xaubet, G. Sanz.
Pulmonary complications after long term amiodarone treatment.
Thorax, 47 (1992), pp. 372-376
[104.]
I. Golstein, M. Topilsky, D. Segev, A. Isakov, I. Heller.
Very early onset of acute amiodarone pulmonary toxicity presenting with hemoptysis.
Chest, 111 (1997), pp. 1.446-1.447
[105.]
H.H. Rotmensch, B. Belhassen, B.N. Swanson, D. Shoshani, S.R. Spielman, A.J. Greenspon, et al.
Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity.
Ann Intern Med, 101 (1984), pp. 462-469
[106.]
W.J. Fulkerson Jr., J.P. Gockerman.
Enfermedad pulmonar inducida por fármacos.
2.ª, pp. 736-754
[107.]
J.I. Kennedy, J.L. Myers, V.J. Plumb, J.D. Fulmer.
Amiodarone pul monary toxicity.
Clinical, radiologic. and pathologic correlations. Arch Intern Med, 147 (1987), pp. 50-55
[108.]
B.D. Wilson, M.L. Lippmann.
Susceptibility to amiodarone-induced pulmonary toxicity: relationship to the uptake of amiodarone by isolated lung cells.
Lung, 174 (1996), pp. 31-41
[109.]
O. Parra, J. Ruiz, I. Ojanguren, J.J. Navas, J. Morera.
Amiodaronetoxicity: recurrence of intersticial pneumonitis after withdrawal of the drug.
Eur Respir J, 2 (1989), pp. 905-907
[110.]
P.B. Corr, R.W. Gross, B.E. Sobel.
Amphiphatic metabolites and membrane dysfunction in ischemic myocardium.
Circ Res, 55 (1984), pp. 135-154
[111.]
W.C. Duane, A.P. McHale, C.E. Sievert.
Lysolecithin-lipid interactions in disruption of the canine gastric mucosal barrier.
Am J Physiol, 250 (1986), pp. 275-279
[112.]
P.G. Reinhart, C.G. Gairola.
Amiodarone-induced pulmonary toxicity in Fischer rats: release of tumor necrosis factor alpha and transforming growth factor beta by pulmonary alveolar maerophages.
J Toxicol Environ Health, 52 (1997), pp. 353-365
[113.]
Y. Futamura.
Amiodarone induces two different types of disorders in mouse alveolar macrophages.
Jpn J Pharmacol, 74 (1997), pp. 21-28
[114.]
Y. Futamura.
Toxicity of amiodarone on mouse pulmonary endothelial cells cultured with or without alveolar macrophages.
J Toxicol Sci, 21 (1996), pp. 253-267
[115.]
W.J. Martin.
Mechanisms of amiodarone pulmonary toxicity.
Clin Chest Med, 11 (1990), pp. 131-138
[116.]
J.R. Donado, A. López, J.M. Echave.
Toxicidad pulmonar recurrente por amiodarona tras retirada del fármaco y tratamiento con corticoides.
Arch Bronconeumol, 31 (1995), pp. 426-428
[117.]
F.E. Marchlinski, T.S. Gansler, H.L. Waxman, M.E. Josephson.
Amiodarone pulmonary toxicity.
Ann Intern Med, 97 (1982), pp. 839-845
[118.]
W.J. Martin II., D.M. Howard.
Amiodarone-induced lung toxicity: in vitro evidence for the direct toxicity of the drug.
Am J Pathol, 120 (1985), pp. 344-350
[119.]
G.N. Kay, A.E. Epstein, J.K. Kirklin, A.G. Diethelm, G. Grayban, V.J. Plumb.
Fatal postoperative amiodarone pulmonary toxicity.
Am J Cardiol, 62 (1988), pp. 490-492
[120.]
D.L. Wood, M.J. Osborn, J. Rooke, D.R. Holmes.
Amiodarone pulmonary toxicity. Report of two cases associated with rapidly Progressive fatal adult respiratory distress syndrome after pulmonary angiography.
Mayo Clin Proc, 60 (1985), pp. 601-603
[121.]
J.L. Fellahi, J. Texereau, G. Chironi, S.D. Qanadli, F. Jardín.
Prise en charge d’une pneumopathie toxique grave a Famiodarone par le monoxyde d’azole inhale.
Rev Pneumol Clin, 53 (1997), pp. 210-221
[122.]
M. Heras, J. Roca, G. Sanz, R. Rodríguez-Roisín, F. Navarro, M. Magriña, A. Agustí-Vidal, A. Betriu.
Alteraciones subclínicas producidas por el tratamiento prolongado con amiodarona.
Rev Esp Cardiol, 40 (1987), pp. 44-50
[123.]
P.J. Kundenchuck, D.J. Pierson, H.L. Greene, E.L. Graham, G.K. Sears, G.B. Trobaugh.
Prospective evaluation of amiodarone pulmonary toxicity.
Chest, 86 (1984), pp. 541-548
[124.]
A.R.A. Sovijarvi, M. Lemola, B. Stenius, J. Idanpaan-Heikkila.
Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions.
Scand J Resp Dis, 58 (1977), pp. 41-50
[125.]
L. Holmberg, G. Boman, L.E. Bottigcr, B. Eriksson, R. Spross, A. Wessling.
Adverse reactions to nitrofurantoin.
Analysis of 921 reports. Am J Med, 69 (1980), pp. 733-738
[126.]
E.C. Rosenow III..
Drug-induced pulmonary disease.
Textbook of respiratory medicine., pp. 1.681-1.702
[127.]
R.G. Fraser, J.A. Peter Paré, P.D. Paré, R.S. Fraser, G.P. Genereux.
3.ª, pp. 2.434-2.437
[128.]
G.L. Zagelbaum, J.A. Peter Paré.
Manual de cuidados intensivos respiratorios.
Barcelona: Salvat, (1985), pp. 259-275
[129.]
A. Xaubet.
Concepto y etiología.
Fibrosis pulmonar., pp. 1-3
[130.]
W.J. Martin II., J.E. Gadek, G.W. Hunninghake, R.G. Crystal.
Oxidant injury of lung parenchymal eells.
J Clin Invest, 68 (1981), pp. 1.277-1.288
[131.]
D.M. Hasby, R.B. Fox, R.N. Harada, J.E. Repine.
Reduction of ede ma of acute hyperoxic lung injury by granulocyte depletion.
J Appl Physiol, 52 (1982), pp. 1.237-1.244
[132.]
N. Gross, D. Smith.
Impaired surfactant phospholipid metabolism in hiperoxic mouse lungs.
J Appl Physiol, 51 (1981), pp. 1.198-1.203
[133.]
R.M. Jackson.
Molecular, pharmacologic and clinical aspects of oxygen-induced lung injury.
Clin Chest Med, 11 (1990), pp. 73-86
[134.]
P.J. Fracica, S.P. Caminiti, C.A. Piantadosi, F.G. Duhaylongsod, J.D. Crapo, S.L. Young.
Natural surfactant and hyperoxic lung injury in primates II.
Morphometric analyses. J Appl Physiol, 76 (1994), pp. 1.002-1.010
[135.]
J.E. Heffner, S.A. Sahn.
Salicylate-indueed pulmonary edema: clinical features and prognosis.
Ann lntern Med, 95 (1981), pp. 405-409
[136.]
R.E. Bowers, K.L. Brigham, P.J. Owen.
Salicylate pulmonary edema: the mechanism in sheep and review of the clinical literature.
AmRev Respir Dis, 115 (1977), pp. 261-268
[137.]
R.J. Zitnik, A.D. Cooper.
Pulmonary disease due to antirheumatic agents.
Clin Chest Med, 11 (1990), pp. 139-150
[138.]
E.C. Rosenow III., W.J. Martin II..
Drug-induced interstitial lung disease.
Interstitial lung disease, 2.ª, pp. 255-270
[139.]
P.E. Parsons.
Respiratory failure as a result of drug overdoses and posonings.
Clin Chest Med, 15 (1994), pp. 93-102
[140.]
Y. Shiota, J.G. Wilson, H. Matsumoto, M. Munemasa, M. Okamura, J. Hiyama, et al.
Adult respiratory distress syndrome induced by a Chinese medicine.
Kamisyoyo-San. lntern Med, 35 (1996), pp. 494-496
[141.]
D.P. Meeker, H.P. Wiedemann.
Drug-induced bronchospasm.
Clin Chest Med, 11 (1990), pp. 163-175
[142.]
T.K. Aldrich, D.J. Prezant.
Adverse effects of drugs on the respiratory muscles.
Clin Chest Med, 11 (1990), pp. 177-189
[143.]
J. McCarren.
Drug-induced lung disease.
Manual of clinical problems in pulmonary medicine., pp. 343-350
[144.]
H.E. Kaeser.
Drug-induced myasthenic syndromes..
Acta Neurol Scand, 70 (1984), pp. 39-47
Copyright © 1999. Sociedad Española de Neumología y Cirugía Torácica
